Nykode Therapeutics Share Price
Stocks
VACC
NO0010714785
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.380 NOK | -3.98% |
|
+5.96% | +40.13% |
| Market Cap | 110.37Cr 12Cr 10Cr 9.41Cr 8.64Cr 16Cr 1.11TCr 17Cr 110.95Cr 44Cr 552.86Cr 44Cr 43Cr 1.85TCr | P/E 2026 * |
-5.23x | P/E 2027 * | -36.5x |
|---|---|---|---|---|---|
| Enterprise Value | 62Cr 6.52Cr 5.67Cr 5.28Cr 4.84Cr 9.15Cr 622.42Cr 9.29Cr 62Cr 24Cr 309.87Cr 24Cr 24Cr 1.04TCr | EV / Sales 2026 * |
-
| EV / Sales 2027 * | 3.25x |
| Free-Float |
56.4% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Nykode Therapeutics
| 1 day | -3.98% | ||
| 1 week | +5.96% | ||
| 1 month | +4.97% | ||
| 3 months | +4.81% | ||
| 6 months | +6.49% | ||
| Current year | +40.13% |
| 1 week | 3.08 |  | 3.56 |
| 1 month | 2.66 | | 3.56 |
| Current year | 2.21 | | 4.1 |
| 1 year | 1.44 | | 4.1 |
| 3 years | 1.44 | | 30.18 |
| 5 years | 1.44 | | 85.3 |
| 10 years | 1.44 | | 93 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Engsig
CEO | Chief Executive Officer | 54 | 01/01/2019 |
| President | 49 | 01/01/2017 | |
Harald Gurvin
DFI | Director of Finance/CFO | 51 | 03/05/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 54 | - | |
Trygve Lauvdal
BRD | Director/Board Member | 57 | - |
Susanne Stuffers
CHM | Chairman | 45 | 23/04/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 27/03/25 | Buy | Company | 30,00,000 | 0.9187% | ||
| 20/12/24 | Buy | Director | 1,00,000 | 0.0306% | ||
| 20/12/24 | Sell | Director | 1,00,000 | 0.0306% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.98% | +5.96% | +85.10% | -88.41% | 12Cr | |
| +2.35% | +2.74% | +33.41% | +79.20% | 5.65TCr | |
| -0.21% | -7.38% | +25.34% | +63.02% | 5.36TCr | |
| -2.44% | +1.40% | -15.74% | -16.80% | 2.29TCr | |
| -2.85% | -7.78% | -8.09% | +346.36% | 2.14TCr | |
| +2.49% | -0.92% | +20.31% | -12.15% | 2.03TCr | |
| +0.79% | -1.06% | +29.29% | -33.32% | 1.76TCr | |
| +0.58% | -5.88% | +16.30% | +540.37% | 1.47TCr | |
| -5.25% | -4.23% | +46.41% | +169.05% | 1.33TCr | |
| +3.41% | -6.61% | +163.08% | +280.43% | 1.35TCr | |
| Average | -0.51% | -2.82% | +39.54% | +132.77% | 2.34TCr | |
| Weighted average by Cap. | +0.23% | -2.96% | +28.70% | +119.88% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | 16Cr 1.7Cr 1.48Cr 1.38Cr 1.27Cr 2.39Cr 162.69Cr 2.43Cr 16Cr 6.38Cr 81Cr 6.4Cr 6.26Cr 271.59Cr |
| Net income | -21Cr -2.19Cr -1.9Cr -1.77Cr -1.63Cr -3.07Cr -209.18Cr -3.12Cr -21Cr -8.2Cr -104.14Cr -8.23Cr -8.05Cr -349.19Cr | -4.16Cr -43.83L -38.1L -35.46L -32.56L -61.48L -42Cr -62.43L -4.18Cr -1.64Cr -21Cr -1.65Cr -1.61Cr -70Cr |
| Net Debt | -49Cr -5.11Cr -4.44Cr -4.14Cr -3.8Cr -7.17Cr -488.08Cr -7.28Cr -49Cr -19Cr -242.99Cr -19Cr -19Cr -814.78Cr | -58Cr -6.09Cr -5.29Cr -4.93Cr -4.52Cr -8.54Cr -581.05Cr -8.67Cr -58Cr -23Cr -289.27Cr -23Cr -22Cr -969.97Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/26/31 | NOK 3.380 | -3.98% | 9,23,327 |
| 30/26/30 | NOK 3.520 | +10.52% | 31,50,808 |
| 29/26/29 | NOK 3.185 | -0.47% | 4,99,502 |
| 28/26/28 | NOK 3.200 | -0.47% | 3,85,749 |
| 27/26/27 | NOK 3.215 | +0.78% | 7,07,807 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VACC Stock
Select your edition
All financial news and data tailored to specific country editions
